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Introduction
Although juvenile rheumatoid arthritis (JRA) is the most
common cause of disability in children, its etiology is
unknown. Immune dysregulation appears to play a key
pathogenic role, as circulating autoantibodies are common
in patients with certain JRA clinical subtypes [1–7]. Two
recent studies have shown a highly significant association
between early-onset pauciarticular JRA and circulating
antibodies to the 43-kDa nuclear protein DEK [8,9].
Although circulating DEK antibodies have subsequently
been found in children and adults with other autoimmune
diseases [10,11], these two studies did reveal that chil-
dren with JRA are significantly more likely to have anti-DEK
antibodies than are children without rheumatic disease.
Children with pauciarticular-onset JRA were also signifi-
cantly more likely to have anti-DEK antibodies than were
children with polyarticular-onset or systemic-onset JRA or
other rheumatic diseases. Among children with pauciartic-
ular JRA, DEK autoantibodies were significantly more
common in those with JRA-associated uveitis than in
those without eye disease [8,9]. DEK reactivity was also
found to be strongly associated with onset of any JRA
subtype before age 6 years [8].
DEK is a nuclear protein that is not structurally related to
any known family of proteins [12,13]. Although it may also
participate in DNA replication and RNA processing
[14,15], we have identified DEK as a DNA-binding protein
that recognizes the TG-rich peri-ets (pets) regulatory
element in the human immunodeficiency virus type 2
(HIV-2) enhancer [16]. The pets site is important in medi-
ating HIV-2 enhancer stimulation in activated T cells and
bp = base pair(s); EMSA = electrophoretic mobility shift assay; HIV = human immunodeficiency virus; JRA = juvenile rheumatoid arthritis; Kd[app] =
apparent dissociation constant; PCR = polymerase chain reaction; pets = peri-ets; rDEK = recombinant DEK protein.
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Abstract
Using electrophoretic mobility shift assays, we examined
sequence-specific binding of DEK, a potential autoantigen in
juvenile rheumatoid arthritis, to conserved Y-box regulatory
sequences in class II MHC gene promoters. Nuclear extracts
from several cell lines of different phenotypes contained
sequence-specific binding activity recognizing DRA,
DQA1*0101, and DQA1*0501 Y-box sequences. Participation
of both DEK and NF-Y in the DQA1 Y-box binding complex
was confirmed by ‘supershifting’ with anti-DEK and anti-NF-Y
antibodies. Recombinant DEK also bound specifically to the
DQA1*0101 Y box and to the polymorphic DQA1*0501 Y box,
but not to the consensus DRA Y box. Measurement of the
apparent dissociation constants demonstrated a two- to
fivefold difference in DEK binding to the DQA1 Y-box
sequence in comparison with other class II MHC Y-box
sequences. Residues that are crucial for DEK binding to the
DQA1*0101 Y box were identified by DNase I footprinting. The
specific characteristics of DEK binding to these related
sequences suggests a potential role for DEK in differential
regulation of class II MHC expression, and thus in the
pathogenesis of juvenile rheumatoid arthritis and other
autoimmune diseases.
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monocytes [17–19], suggesting that DEK may play an
immunomodulatory role as it participates in transcriptional
activation through this and related sites.
Observed sequence similarity between the DEK-binding
site in HIV-2 and the highly conserved Y-box regulatory
element in MHC class II gene promoters pointed to the
Y box as one possible related site. NF-Y binding to the
MHC class II gene Y box anchors a complex assembly of
nuclear proteins that occupies several regulatory elements
over a great distance [20–22]. In the DQA1 promoter
Y box, a reverse CCAAT motif with a partially overlapping
TG-rich sequence shares sequence identity with the
HIV-2 DEK-binding site at 7 of 10 positions (Fig. 1). In the
DQA1*0501 allele, which is highly associated with predis-
position to autoimmune disease [23–27], the Y box con-
tains a single-nucleotide polymorphism that reduces
sequence identity to 6 of 10 positions. We hypothesized
that DEK could bind in a sequence-specific manner to the
Y-box motifs in the promoter regions of several class II
MHC genes, and that gene- and allele-specific Y-box poly-
morphisms could affect DEK binding activity. In this study,
we examine the characteristics of DEK binding to the
Y-box sequences of DQA1*0101, DQA1*0501, DRA,
DQB, and DRB. We also confirm participation of DEK
with NF-Y in the DQA1 Y-box binding complex and local-
ize specific DEK binding within this sequence. As the
Y-box promoter element is crucial to the regulation of
MHC class II gene expression, sequence-specific binding
to this motif indicates a potential role for DEK in modulat-
ing normal and abnormal immune response.
Materials and methods
Cell culture and preparation of nuclear extracts
Cultured cell lines were grown and harvested and nuclear
extracts were prepared from resting cells as previously
described [28,29].
Preparation of partially purified recombinant DEK protein
Construction of the poly-histidine-tagged DEK bacterial
expression vector is described elsewhere [16]. Full-length
DEK or antisense DEK was prepared from cultures grown
from individual colonies to log phase, induced with 1 mm
isopropyl thiogalactose, and harvested by centrifugation
after 4 hours. Recombinant protein was purified from bac-
terial lysates in accordance with the published method for
the QIAexpress system (Qiagen, Valencia, CA, USA) with
variations in Buffers B and D as noted in Supplementary
material. Procedures were carried out at 4°C; dialyzed
recombinant DEK protein (rDEK) was stored at –80°C.
Preparation of FLAG-DEK
A FLAG-tagged DEK adenoviral vector constructed by the
University of Michigan Vector Core was used to transduce
T98G cells (ATCC) by incubation for 48 hours before
harvesting for immunoprecipitation. FLAG-DEK was
immunoprecipitated using anti-FLAG resin (Sigma-Aldrich,
St Louis, MO, USA) in accordance with the manufactur-
er’s instructions and was eluted by competition with
peptide containing three FLAG recognition epitopes.
Electrophoretic mobility shift assays (EMSAs)
EMSAs were carried out as previously described [30],
using 0.1–0.25 ng of radiolabeled oligonucleotide probe
(2.5 × 104 counts per minute) per 15 µl binding reaction
and 5 µg of nuclear extract (except as noted) or <1 µg of
rDEK. For competition EMSAs, unlabeled double-stranded
oligonucleotide was added to reaction mixtures before the
radiolabeled probe. For antibody supershift of binding
complexes, 1 µl anti-NF-YA antibody (gift of JP-Y Ting) or
1 µl high-titer anti-DEK human serum (gift of W Szer [9])
or 2–3 µl control human serum was added to the binding
reaction, and the mixture was incubated on ice for 2 hours
before the probe was added.
Sequence of oligonucleotide probes and competitors
See Fig. 1.
Measurement of apparent dissociation constants using
EMSA
The 32P end-labeled oligonucleide probe (5 nM) was incu-
bated with immunoprecipitation-purified FLAG-rDEK in a
Figure 1
EMSA probes and competitors: HIV-2 DEK-binding site, class II MHC
Y-box motifs (DQA1, DRA, DQB, and DRB), and related sequences.
Probes and competitors include only sequences 3′ of the  symbol. 
X boxes are shown to provide a broader context for the Y-box
regulatory element. EMSA = electrophoretic mobility shift assay.
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range of concentrations from one tenth to 10 times the
estimated Kd[app] (apparent dissociation constant) as
described elsewhere [31]. Protein-bound DNA was sepa-
rated from free probe as for EMSA in 1 × TBE (Tris-borate-
EDTA buffer: Tris 89 mM, borate 89 mM, EDTA 2 mM).
The dried gel was exposed to a phosphor screen
overnight, and the bands were quantified using a Molecu-
lar Dynamics Storm 840 Phosphorimager with Image-
Quant Software. The data were fit via nonlinear
least-squares regression to the single-site binding
isotherm:
% free DNA = Kd[app]/( Kd[app] + [protein]).
From this equation, the apparent Kd corresponds to the
protein concentration at which half of the DNA is bound [31].
DNAse I protection assay
The 148-bp probe included DQA1*0101 promoter
sequence from –53 to –200. PCR primer (200 ng) for
probe sequence was end-labeled with 32Pγ-ATP and T4
polynucleotide kinase (New England Biolabs, Beverly, MA,
USA), and was column purified. Labeled antisense primer
(200 ng) and 200 ng unlabeled sense strand primer (or
vice versa) were used in each 50.5-µl PCR reaction, with
0.2 mM dNTP, 1.5 mM MgCl2, 5 µl 10X PCR Buffer (Invitro-
gen, Carlsbad, CA, USA), and 1 µg Namalwa genomic
DNA. Taq polymerase (Invitrogen) was added at 80°C
after a 94°C ‘hot start,’ initiating 35 cycles of PCR: 94°C
for 45 s, 55°C for 30 s, and 72°C for 90 s, with final exten-
sion at 72°C for 10 min. PCR products were purified with
a High Pure PCR Product Purification Kit (Roche Applied
Science, Indianapolis, IN, USA) and then used at
2.5 × 104 CPM/2 µl. DNase I digestion reaction and foot-
printing gel followed published techniques [16].
Results
Y-box binding activity in nuclear extracts is gene- and
allele-specific
The similarity of the DQA1*0101 Y-box sequence to the
HIV-2 DEK-binding site (see Fig. 1) first led us to investi-
gate whether DEK in nuclear extracts binds to MHC
class II Y-box regulatory elements in vitro. With a double-
stranded oligonucleotide probe containing the HLA-
DQA1*0101 Y-box sequence, EMSAs revealed similar
binding activity in nuclear extracts from B lymphoid
(Namalwa), T lymphoid (Jurkat, CEM), monocytoid (U937),
and HeLa cell lines (Fig. 2), and in nuclear extracts from
SKW 6.4 (B lymphoid), KG-1 (T lymphoid), and HL-60
(monocytoid) cell lines (not shown). Electrophoretic pat-
terns with a probe corresponding to the DQA1*0501
Y-box sequence, which diverges from the DQA1*0101
Y-box sequence by a single base pair within the highly
conserved reverse CCAAT sequence, appear to vary with
the cell type, and binding appears weaker than with the
DQA1*0101 probe (see Fig. 2).
Competition EMSAs demonstrated sequence-specificity
of the DQA1*0101 Y-box binding activity (Fig. 3a). Unla-
beled DQA1*0101 oligonucleotides successfully com-
peted for strong binding activity seen in nuclear extracts
from the Namalwa B cell line (Fig. 3a, lanes 3 and 4),
whereas unlabeled DQA1*0501 Y-box sequence com-
peted less well (Fig. 3a, lanes 5 and 6). There was no
competition when the Y-box reverse CCAAT motif was
mutated at all five positions (Fig. 3a, lanes 7 and 8), nor
with the unrelated HIV-1 κB sequence (lane 10). DEK has
been shown to bind to the HIV-2 pets site [16], but
oligonucleotides containing this sequence also failed to
compete significantly (lane 9), suggesting that factors
other than DEK play a role in determining the specificity of
this complex. In particular, NF-Y is the predominant
nuclear factor binding to the Y box [21], and the HIV-2
pets site does not contain the reverse CCAAT sequence
required for NF-Y binding.
Figure 2
Nuclear extracts from several cultured cell lines show DQA1 Y-box-
specific binding activity. Oligonucleotide probes containing the
DQA1*0101 Y-box sequence (lanes 1-7) or DQA1*0501 polymorphic
Y-box sequence (lanes 8-12) bind protein in nuclear extracts prepared
from resting cells of the indicated cultured cell lines. Lane 1, control
without nuclear extract; lanes 2 and 8, 2.5 µg of protein; lanes 3–7 and
9–12, 5 µg of protein.
The consensus (HLA-DRA) Y-box sequence differs from
the HLA-DQA1*0101 Y box by a single nucleotide imme-
diately 5′ of the reverse CCAAT pentamer; this single-
nucleotide polymorphism significantly changes the
electrophoretic pattern (Fig. 3b) in comparison with that
seen with the HLA-DQA1*0101 probe. HLA-DQA1*0101
oligonucleotide also competes poorly with the consensus
Y-box probe for binding (Fig. 3b, lanes 5–6). Divergence
of the HLA-DQA1*0501 Y-box sequence at one position
within the required NF-Y binding site reduces its ability to
compete with the DRA Y-box probe (Fig. 3b, lanes 7–8)
as much as does mutation of all five nucleotides within the
CCAAT sequence (Fig. 3b, lanes 9–10).
Both DEK and NF-Y participate in the HLA-DQA1 Y-box
binding complex
Participation of both DEK and NF-Y in the DQA1 Y-box
binding complex was confirmed by using high-titer anti-
DEK antiserum (gift of W Szer [9]) and monoclonal anti-
body to the NF-YA subunit of the Y-box binding factor (gift
of JP-Y Ting) to further retard the mobility of the DQA1
Y-box binding complex (‘supershifting’) (Fig.4, lanes 3–4).
Preincubation of Namalwa cell nuclear extracts with anti-
bodies to NF-YA also retards the binding complex (Fig.4,
lane 5), leaving a residual band (arrow) which can be attrib-
uted to distinct DEK binding activity. Preincubation with
both antibodies results in further retardation of the binding
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Figure 3
Namalwa cell nuclear protein(s) bind to DQA1 and DRA Y-box elements. 5 µg of Namalwa cell nuclear extract (lanes 2–10) and unlabeled
oligonucleotide competitors were added to the binding reaction before addition of the radiolabeled DQA1*0101 probe (a) or the radiolabeled DRA
probe (b) to define the sequence specificity of nuclear protein binding. In both (a) and (b), lane 1 contains no protein. See Figure 1 for site mutant
and CCAAT mutant sequences. pets = peri-ets.
complex to form a doublet (Fig.4, lane 6). The same elec-
trophoretic patterns were seen after preincubation of
nuclear extracts from the CEM T lymphocytoid cell line with
anti-DEK and anti-NF-YA antibodies (data not shown).
Recombinant DEK protein binds in a sequence-specific
manner to the DQA1 Y box but not to the DRA
(consensus) Y box
Having established that DEK and NF-Y in nuclear extracts
participate in the HLA-DQA1*0101 binding complex, we
used recombinant full-length DEK (rDEK) to determine
whether it alone can bind to Y-box motifs and to examine
how gene- and allele-specific sequence polymorphisms
alter its binding. The HLA-DQA1*0101 Y-box sequence
does bind rDEK specifically, with unlabeled probe
sequence competing successfully for binding (Fig.5a, lanes
4–6). In contrast, despite its identity at 9 of 10 positions,
unlabeled consensus (DRA) Y-box sequence (Fig.5a, lanes
7–8) competes very poorly against the HLA-DQA1*0101
Y-box probe. DQA1*0501 Y-box sequence (Fig.5a, lanes
9–10) competes only slightly less well than does
DQA1*0101, indicating that a change in the residue at
position 7 does not prevent rDEK binding. Mutation of the
reverse CCAAT sequence, however, eliminates effective
competition for binding to the DQA1*0101 Y-box sequence
(Fig.5a, lanes 11–12). Taken together, these results indi-
cate that substitution of adenine at position 3 in the DQA1
Y box for guanine in the consensus Y-box sequence signifi-
cantly strengthens DEK binding, as do bases at positions 5
and 6 in the reverse CCAAT sequence.
Further characterization of rDEK binding to the poly-
morphic DQA1*0501 Y-box sequence and to the consen-
sus (HLA-DRA) Y-box sequence establishes a relative
hierarchy of DEK binding activity (Fig.5b). With the
DQA1*0501 probe, unlabelled DQA1*0101 sequence
(Fig.5b, lane 3) competed less well than did unlabelled
probe. DRA Y box sequence (Fig. 5b, lane 4) and CCAAT
mutant sequence (not shown) did not compete for binding.
Inability of the HLA-DRA Y-box sequence to compete with
the DQA1*0501 probe again indicates the relative impor-
tance of the adenine residue immediately 5′ to the reverse
CCAAT for DEK binding. With the DRA Y-box sequence
as probe (Fig.5b, lanes 6–10), the unlabelled probe
sequence competes less well than do any of the other
Y-box sequences, suggesting that rDEK alone binds to this
sequence nonspecifically and with low affinity.
Quantitative assessment of rDEK binding to related DQ-
and DR- Y-box sequences
Quantification of the apparent dissociation constant (Kd[app])
for rDEK binding to related class II MHC Y-box motifs vali-
dates the relative hierarchy of DEK binding activity
described above, and further emphasizes the contribution of
gene-specific Y-box polymorphisms to DEK binding activity.
As shown in Table 1, DEK binds more strongly to Y-box
sequences in either DQA1 allele than it does to any of the
other DR- or DQ-related Y-box sequences. It binds least
well to the DRA (consensus) Y-box motif, with a Kd[app] that
is approximately five times that for the DQA1 sequences.
The Kd[app] for DEK binding to DQB is approximately four
times that for the DQA1 sequences, whereas the Kd[app] for
DEK binding to the DRB Y-box sequences, especially the
DRB alleles associated with the DR4 haplotype, are inter-
mediate between the two extremes. Once again, the A-to-G
substitution at position 3 in the Y box appears to strengthen
DEK binding to the DQA1 Y box in comparison with the
DRA Y box; allelic variation in the nucleotide at position 7 in
the Y-box sequence (as in DQA1*0501 and in the DR4-
associated DRB Y-box sequence) may also mediate subtle
differences in DEK binding to otherwise identical sites.
Gene-specific sequence polymorphisms outside the Y box
per se could also explain why dissociation constants differ
where Y-box sequences are identical, as in the DQB and
DRB consensus motifs.
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Figure 4
DEK and NF-Y participation in the DQA1*0101 Y-box binding complex
demonstrated by ‘supershift’ assay. Namalwa nuclear extract (5 µg)
was preincubated with the following antibody reagents before addition
of radiolabeled probe containing DQA1*0101 Y-box sequence: lane 2,
no antibody reagent; lane 3, 2 µl normal human serum; lane 4, 1 µl
high-titer anti-DEK human antiserum; lane 5, 1 µl anti-NF-YA (subunit)
monoclonal antibody; lane 6, 1 µl of anti-DEK plus 1 µl of anti-NF-YA
monoclonal antibody. Lane 1 contains probe without nuclear extract or
antibody reagent.
Localization of DEK binding within the Y box
DNase I footprinting with recombinant protein further
defined the physical interaction between DEK and the
HLA-DQA1*0101 Y-box element (Fig. 6). Using the non-
coding strand as probe, consistent protection is seen over
the G at position 7, which is polymorphic in the
DQA1*0501 allele (A-for-G substitution) and in the DRB
alleles associated with the DR4 haplotype (C-for-G substi-
tution). Consistent protection is also seen at position 2,
adjacent to the A-for-G substitution that diverges from the
Y-box consensus sequence, although there is no protec-
tion of the divergent base itself at position 3. DNase I pro-
tection by recombinant DEK extends over the length of the
Y-box sequence, including bases within the NF-Y binding
site (reverse CCAAT sequence), again suggesting that the
two proteins may interact.
Discussion
All antigen-presenting cells upregulate MHC class II tran-
scription in response to immune stimulation. We have pre-
viously shown that activation of promyeloid cells causes
dephosphorylation of DEK and diminished DEK binding to
the HIV-2 long terminal repeat [16,17,32]. In this study,
we show that rDEK can bind to the DQA1 Y box, and that
DEK in nuclear extracts participates in the DQA1 Y-box
binding complex in vitro. Thus, we propose a model in
which intracellular signaling modulates the ability of DEK
to bind DNA, causing alteration of MHC class II transcrip-
Available online http://arthritis-research.com/content/5/4/R226
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Figure 5
Recombinant DEK protein (rDEK) binds in a sequence-specific manner to the DQA1*0101 Y box, but not to the DRA (consensus) Y box. (a) 5 µl
of antisense rDEK (lane 2), 5 µg of Namalwa cell nuclear extract (lane 3), or 5 µl of partially purified recombinant DEK protein (rDEK) (lanes 4–12)
was used in each EMSA binding reaction; rDEK was preincubated with the indicated unlabelled competitor before addition of the DQA1*0101
Y-box probe. Lane 1 contains no protein. (b) The indicated unlabelled oligonucleotide competitors (20 ng) were added to the binding reaction
containing 5 µl of partially purified rDEK before addition of radiolabeled DQA1*0501 probe (lanes 1–4), or radiolabeled DRA probe (lanes 5–8).
PolyD(I-C) (10 ng) was added to each binding reaction as nonspecific competitor. EMSA = electrophoretic mobility shift assay.
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Table 1
Apparent dissociation constant (Kd[app]) of rDEK binding to
class II MHC Y-box sites
Sequence name Y-box sequence Kd[app]a (nM)
DQA1*0101 CTAATTGGCC 478 ± 103
DQA1*0501 CTAATTAGCC 582 ± 130
DRA CTGATTGGCC 2480 ± 519
DQB consensus CTGATTGGTT 1977 ± 93
DRB consensus CTGATTGGTT 1266 ± 274
DRB-DR4 CTGATTCGTT 1041 ± 258
aMean ± standard error, based on at least three determinations.
tion. Transient transfection experiments in cultured cell
lines have not proved useful in examining this model, for
DEK is highly expressed in most cells of hematopoietic
lineage, and further overexpression has resulted in appar-
ently nonspecific downregulation of transcriptional activity
(as might be predicted from [14]). For this reason, we are
currently pursuing other experimental approaches.
The DQA1*0501 promoter region (QAP 4.1), in which a
single-base-pair polymorphism in the Y box significantly
diminishes transcriptional activity [33], is a component of
the so-called susceptibility haplotype for autoimmune
disease. The DQA1*0501 allele is strongly associated
with early-onset pauciarticular JRA in Northern European
populations [23,24] and with increased risk for juvenile
dermatomyositis [25] and Sjögren’s syndrome with high
autoantibody production [26,27]. In our proposed model,
aberrant class II MHC regulation could result from altered
DEK binding and/or interaction with NF-Y, and aberrant
class II expression may alter or enhance reactivity against
DEK-derived or other self peptides. The C-terminal region
of DEK, which contains the putative DNA-binding domain,
appears to be most antigenic [34] (and K Sitwala and DM
Markovitz, unpublished observations), raising the possibil-
ity that altered DNA binding may expose other masked
epitopes. Development of antibodies to DEK could even
be a primary event in the pathogenesis of JRA, with dis-
ruption of nuclear events due to penetration of anti-DEK
antibodies into living cells [35]. It remains to be deter-
mined whether anti-DEK antibodies are directly involved in
the pathogenesis of autoimmune disease, or if they result
from generally enhanced immunoreactivity.
Conclusion
Three specific findings in this report support a potential
role for DEK as a transcriptional modulator of MHC class II
expression. One is that DEK binds to the HLA-DQA1
Y box in a sequence-specific manner. Another is that NF-Y
and DEK both participate in the HLA-DQA*0101 Y-box
binding complex, which coordinates DQ protein expres-
sion. Finally, DEK binds differentially to specific Y-box
sequences found in HLA-DQA1(*0101 and *0501 alleles)
and HLA-DRA, consistent with observations of DQA1
gene-specific cell-surface expression [36] and allele-spe-
cific promoter activity [33]. The specificity of rDEK binding
to these and other, related Y-box sequences (including
HLA-DQB and HLA-DRB alleles associated with the DR4
haplotype) may correlate with a predisposition to autoim-
mune disease seen with certain HLA haplotypes.
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Supplementary material
Buffer B (6 M urea, 0.1 M NaH2PO4, 10 mm Tris-l, 0.1 M
KCl), used for cell lysis and protein elution, was prepared
with the addition of imidazole (final concentration 25 mm)
and urea (final concentration approximately 8 M). Qiagen
Ni-NTA Superflow resin was equilibrated with modified
buffer B before being combined with the cell lysate. The
cell lysate–resin combination was incubated at 4°C for 1.5
hours. Purified protein was eluted from the column with
buffer B containing 100–250 mm imidazole. The presence
and size of rDEK bands were verified by western blotting.
Protein in positive elution fractions was refolded to native
structure by serial dialysis against buffer D (20 mm
HEPES, 0.1 M KCl, 0.2 mm EDTA, 0.5 mm dithiothreitol,
0.5 mm phenylmethylsulfonyl fluoride, 20% glycerol) con-
taining stepwise decreasing concentrations of urea (6 M
for 2 hours, 4 M for 2 hours, 2 M for 2 hours, no urea for
12 hours).
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